SCHOLAR ROCK HOLDING CORP (SRRK)

Company Profile

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2018-05-24. The firm is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The firm is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.

Company Info

SCHOLAR ROCK HOLDING CORP

301 Binney Street, 3rd Floor

Cambridge MASSACHUSETTS 02142

P: 18572593860

CEO: Stuart A. Kingsley

Employees: 114

Website: https://scholarrock.com/